Mr. Nasser Hassan has over 30 years of experience in developing commercial products within the life sciences industry, from proof of concept to commercialization. This has included working on product commercialization of multiple biopharmaceutical products that have individually exceeded over a billion dollars in global sales. Mr. Hassan supported the development of the Phase II clinical/preclinical gene therapy programs at VIRxSYS, and was the Chief Operating Officer for Bamboo Therapeutics, where he was key in its development and sale to Pfizer for $650 million. Mr. Hassan is the Chief Executive Officer for Breakthrough BioAssets (BBA), which is a life sciences and health IT operating company that licenses, acquires and develops strong scientific and technology assets that have a social and commercial impact. He also provides C-level and board-level support to multiple companies within BBA portfolio companies. Mr. Hassan’s previous roles included senior positions within AstraZeneca, Merck KGaA and GSK.